SubscribeLogin
Published

IDH Inhibitor Activity in Brain Cancer Persists With Longer Follow-Up

Summary by MedPage Today
HOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

CancerCancer
Breast CancerBreast Cancer
Houston, TexasHouston, Texas
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal